Early switch to fingolimod may decrease the risk of disease recurrence after natalizumab interruption

Saved in:
Bibliographic Details
Published in:Multiple sclerosis 2013-08, Vol.19 (9), p.1236-1237
Main Authors: Laroni, A, Brogi, D, Milesi, V, Abate, L, Uccelli, A, Mancardi, GL
Format: Article
Language:English
Subjects:
Antibodies, Monoclonal, Humanized - administration & dosage
Drug Substitution
Female
Fingolimod Hydrochloride
Humans
Immunologic Factors - administration & dosage
Multiple Sclerosis, Relapsing-Remitting - drug therapy
Natalizumab
Propylene Glycols - administration & dosage
Sphingosine - administration & dosage
Sphingosine - analogs & derivatives
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:
ISSN:1352-4585
1477-0970
DOI:10.1177/1352458512468498